Disclosures

Al B. Benson III, MD

Professor, Medicine, Hematology Oncology Division, Feinberg School of Medicine; Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Served on scientific advisory board or as a consultant or expert witness for Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, EMD Serono, Exelixis Inc., Genentech, Inc., Genomic Health, Inc., ImClone Systems Incorporated, Merck & Co., Inc., National Cancer Institute, Oncosil Medical, sanofi-aventis U.S., Spectrum Pharmaceutics, and Taiho Pharmaceuticals Co., Ltd.

Daniel G. Coit, MD

Surgical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Reported no conflicts of interest

David S. Ettinger, MD

Alex Grass Professor in Oncology; Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Received clinical research support/data safety monitoring board from Golden Biotechnology

Served on scientific advisory board or as a consultant or expert witness for AbbVie, BeyondSpring Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono, Genentech, Inc., Guardant Health, Inc., Helsinn Therapeutics (US), Inc., Herron Therapeutics, McGivney Global Consultants, and Trovagene, Inc.

William J. Gradishar, MD

Director, Clinical Network; Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Served on scientific advisory board or as a consultant or expert witness for Genentech, Inc.

Served on promotional advisory board or speakers bureau for Genomic Health

Received patent, equity, or royalty from Biotheranostics and MGI Pharma, Inc.

Aparna Kalyan,  MBBS

Assistant Professor of Medicine (Hematology and Oncology), Northwestern Medicine, Feinberg School of Medicine, Chicago

Reported no conflicts of interest

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from Abbott Laboratories, Amgen, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical Products, LP, Kite Pharma, MedImmune Inc., Merck & Co., Inc., Roche Laboratories, Inc., sanofi-aventis U.S., and Takeda Pharmaceuticals North America, Inc.

Served on scientific advisory board or as a consultant or expert witness forAbbott Laboratories, Amgen Inc., Celgene Corporation, Janssen Pharmaceutical Products, LP, Karyopharm, Kite, Merck & Co., Inc., Oncopeptides, Reddy’s Laboratory, and Takeda Pharmaceuticals North America, Inc.

Richard J. Lee, MD, PhD

Assistant Professor of Medicine, Massachusetts General Hospital/Dana-Farber Cancer Institute, Brigham & Women’s Cancer Center

Served on scientific advisory board or as a consultant or expert witness for Boehringer Ingelheim, GmbH; Bayer HealthCare Pharmaceuticals LLC; and Janssen Pharmaceutica Products, LP.

Karl D. Lewis, MD

Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine

Received clinical research support from or served on data safety monitoring board for Regeneron Pharmaceuticals, Inc., and Roche Laboratories, Inc.

Served on scientific advisory board or as a consultant or expert witness for Genentech, Inc., Regeneron Pharmaceuticals, Inc., and Sun Pharma 

Ursula A. Matulonis, MD

Professor of Medicine, Harvard Medical School; Director, Gynecologic Oncology; Brock-Wilson Family Chair, Dana-Farber Cancer Institute, Boston

Served on scientific advisory board or as a consultant or expert witness for 2X Oncology, AstraZeneca, Clovis, Fujifilm, Geneos, Myriad Genetic Laboratories, Syntax, and Tesaro

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board as principal investigator for Novartis Pharmaceuticals Corporation

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals North America, Inc., and Pfizer, Inc.

James L. Mohler, MD

Associate Director and Senior Vice President of Translational Research; Chief, Inter-Institutional Academics; Professor of Oncology, Roswell Park Comprehensive Cancer Center

Reported no conflicts of interest

Robert J. Motzer, MD

Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York

Served on scientific advisory board or as a consultant or expert witness for Genentech, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.

David G. Pfister, MD

Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board for AstraZeneca, Bayer HealthCare, Boehringer Ingelheim GmbH, Eli Lilly and Company, Exelixis Inc., Genentech, Inc., GlaxoSmithKline, Incyte Corporation, MedImmune Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation 

Served on scientific advisory board or as a consultant or expert witness for Incyte Corporation and Merck & Co., Inc.

Michael A. Postow, MD

Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Array BioPharma, Infinity Pharmaceuticals, and Rgenix, Inc.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Array BioPharma, Merck & Co., Inc., Incyte Corporation, and Newlink Genetics

Jerald P. Radich, MD

Professor, University of Washington School of Medicine; Member, Clinical Research Division, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle

Served on scientific advisory board or as a consultant or expert witness for Novartis Pharmaceuticals Corporation and Seattle Genetics

Vatche Tchekmedyian, MD

Hematologist and Oncologist, Brigham & Women's Hospital Internal Medicine, Boston

Holds stock in Infinity Pharmaceuticals, Inc., Halozyme Therapeutics, Inc., Global Blood Therapeutics, Portola Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., and BioMarin Pharmaceutical

Medical Writers:

Melissa Eng

Serves as Research Coordinator at the Northwell Health Clinical Trials Office

Nahae Kim

Serves as Assistant Research Coordinator for Northwell Health

The following individuals contributing to JNCCN 360 reported no relevant conflicts of interest:

Angel Au-Yeung; Meg Barbor, MPH; Sarah Campen, PharmD; Joseph Cupolo; Cordi Craig; Celeste L. Dixon; Laura Entis; Joseph Fanelli; Andrew Goldstein; Emir Hadzic, PhD; Sarah Jackson; Julian Lim; Susan London; Margie Miller; Anna Nowogrodzki; Hillary Ojeda; Susan Reckling; Kayci Reyer; and Sara Tewksbury